Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Mezagitamab · TAK-079

Monoclonal antibody · Antagonist of CD38 · developed by TAKEDA PHARMACEUTICAL CO

Phase 3 Most advanced trial

TAK Developer

1 Registered trials

What is Mezagitamab?

Mezagitamab is a human IgG1 monoclonal antibody that binds CD38 on plasmablasts, plasma cells, NK cells, and activated T and B cells. It triggers antibody-dependent cellular cytotoxicity and cell lysis without inducing CD38-dependent signaling. It is studied in immune thrombocytopenic purpura.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: TAK-079
Drug type: Monoclonal antibody
Targets: CD38
Mechanism: Antagonist of CD38
Pathways: antibody-dependent cellular cytotoxicity, cell lysis
Therapy area: Hematology, Immunology
Developer: TAKEDA PHARMACEUTICAL CO (TAK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 0XMR8L9LOL

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06948318	Phase 3	Immune Thrombocytopenic Purpura (ITP)	Recruiting	TAK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Immune Thrombocytopenic Purpura (ITP)

Other drugs acting on CD38

ABBV-438 Phase 1 Felzartamab Phase 3

More from TAKEDA PHARMACEUTICAL CO

Maribavir FDA approved Susoctocog Alfa FDA approved Vedolizumab FDA approved Vonicog Alfa FDA approved Elritercept Phase 3 GDX012 Phase 1/2 IGI Phase 3 MNI-792 Phase 1 Pevonedistat Phase 2/3 Soticlestat Phase 3 TAK-186 Phase 1/2 TAK-188 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the TAK page.

Follow TAK, the company behind Mezagitamab

See TAK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TAK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z